Biotage AB (publ)
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation produ… Read more
Biotage AB (publ) (BITGF) - Total Liabilities
Latest total liabilities as of March 2025: $862.00 Million USD
Based on the latest financial reports, Biotage AB (publ) (BITGF) has total liabilities worth $862.00 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biotage AB (publ) - Total Liabilities Trend (2014–2024)
This chart illustrates how Biotage AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biotage AB (publ) Competitors by Total Liabilities
The table below lists competitors of Biotage AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Luxin Venture Capital Group Co Ltd
SHG:600783
|
China | CN¥4.54 Billion |
|
Tangrenshen Group Co Ltd
SHE:002567
|
China | CN¥11.73 Billion |
|
Guizhou Redstar Developing Co Ltd
SHG:600367
|
China | CN¥549.65 Million |
|
Cal-Comp Electronics (Thailand) Public Company Limited
BK:CCET
|
Thailand | ฿54.15 Billion |
|
Lsb Industries Inc
NYSE:LXU
|
USA | $644.94 Million |
|
Bright Dairy & Food Co Ltd
SHG:600597
|
China | CN¥11.39 Billion |
|
Centuria Capital Group
PINK:CNECF
|
USA | $2.08 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Biotage AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotage AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotage AB (publ) (2014–2024)
The table below shows the annual total liabilities of Biotage AB (publ) from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $991.00 Million | -22.21% |
| 2023-12-31 | $1.27 Billion | +81.48% |
| 2022-12-31 | $702.00 Million | +13.23% |
| 2021-12-31 | $620.00 Million | +39.51% |
| 2020-12-31 | $444.40 Million | -3.43% |
| 2019-12-31 | $460.19 Million | +52.87% |
| 2018-12-31 | $301.02 Million | +102.59% |
| 2017-12-31 | $148.59 Million | +12.60% |
| 2016-12-31 | $131.96 Million | +8.01% |
| 2015-12-31 | $122.17 Million | +5.00% |
| 2014-12-31 | $116.36 Million | -- |